Echinococcus InfectionsNCT06109012
Multiple Disseminated Hydatidosis With Rare Locations
An observational study of Echinococcus Infections, run by Faculty Of Medicine And Pharmacy, Casablanca at 1 site in Morocco.
Trial summary
Hydatid disease is an anthropozoonosis due to the development of the larval form of Echinococcus granulosus in the human body, which constitutes a 'dead-end' host. It's a common parasitosis in North African countries and constitutes a public health problem in Morocco. Read more about this study
- Who is it for?
- Ages 44 to 44 years, men only
- Conditions the study is for
- Echinococcus Infections
- What is being tested?
- duct diversion
- Type of treatment
- Surgery or procedure
- How many people
- 1 participants
- Where
- 1 siteMorocco
- Study dates
- 1 Sep 2021to 30 Sep 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 44 to 44 years
- Men only
- No healthy volunteers
- Adult
Study population: This is a descriptive study of a single patient with the particularity of having exceptional locations of hydatidosis.
Who may be able to join
- none
Who cannot join
- none
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Multiple Disseminated Hydatidosis With Rare Locations: Mediastinal, Pancreatic and Pelvic: Case Report
Hydatid disease is an anthropozoonosis due to the development of the larval form of Echinococcus granulosus in the human body, which constitutes a 'dead-end' host. It's a common parasitosis in North African countries and constitutes a public health problem in Morocco. The liver and lung are the most affected while the mediastinum, pancreas and pelvis are rarely affected. We report the case of a 40-year-old patient operated 15 years ago for cerebral and cervical hydatid cysts and who was hospitalized for generalized mucocutaneous jaundice. On exploration, we discover the presence of disseminated abdominal hydatidosis with association of 3 rare locations: mediastinal, pancreatic and pelvic. Indirect diagnostic tests were positive: indirect hemagglutination (IHA) and Elisa. The Western blot test also showed the presence of specific bands, thus making it possible to retain the diagnosis of hydatidosis.
The hydatid cyst with mediastinal, pancreatic and pelvic location is rare and their association is very exceptional. It is essential to evoke the hydatid origin of any cystic lesion in a patient staying in an endemic area.
- Conditions
- Echinococcus Infections
- Being tested
- duct diversion
- Keywords
- echinococcus, serology, multiple locations
- Medical subject headings
- Echinococcosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
duct diversionProcedure or surgery
the patient benefited from a diversion of the bile ducts complicated by ruptured cysts with anaphylactic shock
What is being measured
The primary outcome is the main question the study is designed to answer.
THE PATIENT DIED due to probably anaphylactic shock
the patient probably had the rupture of cysts during the surgical procedure with anaphylactic shock as a complication
Measured: 1 mounth
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Oct 2023
- Study start1 Sep 2021
- Primary completion20 Sep 2021
- Study completion30 Sep 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Echinococcus InfectionsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 1 participants (actual)
Sponsor and investigators
- Lead sponsor
- Faculty Of Medicine And Pharmacy, Casablanca
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, BENNANE WAFAA, Faculty Of Medicine And Pharmacy, Casablanca
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06109012
- Sponsor's protocol ID
- multiple hydatidose
- Status last verified
- Oct 2023
- First submitted
- 26 Oct 2023
- Last updated
- 31 Oct 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 31 Oct 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multiple Disseminated Hydatidosis With Rare Locations: Mediastinal, Pancreatic and Pelvic: Case Report
- ClinicalTrials.gov ID
- NCT06109012
- Acronym / sponsor ID
- multiple hydatidose
- Conditions
- Echinococcus Infections
- Keywords
- echinococcus, serology, multiple locations
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1 participants (actual)
- Lead sponsor
- Faculty Of Medicine And Pharmacy, CasablancaUniversity, hospital or other
- Study start
- 1 Sep 2021 (actual)
- Primary completion
- 20 Sep 2021 (actual)
- Study completion
- 30 Sep 2021 (actual)
- First posted
- 31 Oct 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Hydatid disease is an anthropozoonosis due to the development of the larval form of Echinococcus granulosus in the human body, which constitutes a 'dead-end' host. It's a common parasitosis in North African countries and constitutes a public health problem in Morocco. The liver and lung are the most affected while the mediastinum, pancreas and pelvis are rarely affected. We report the case of a 40-year-old patient operated 15 years ago for cerebral and cervical hydatid cysts and who was hospitalized for generalized mucocutaneous jaundice. On exploration, we discover the presence of disseminated abdominal hydatidosis with association of 3 rare locations: mediastinal, pancreatic and pelvic. Indirect diagnostic tests were positive: indirect hemagglutination (IHA) and Elisa. The Western blot test also showed the presence of specific bands, thus making it possible to retain the diagnosis of hydatidosis.
The hydatid cyst with mediastinal, pancreatic and pelvic location is rare and their association is very exceptional. It is essential to evoke the hydatid origin of any cystic lesion in a patient staying in an endemic area.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Ages
- 44 to 44 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- This is a descriptive study of a single patient with the particularity of having exceptional locations of hydatidosis.
Key inclusion criteria (1 listed)
- none
Key exclusion criteria (1 listed)
- none
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| duct diversionthe patient benefited from a diversion of the bile ducts complicated by ruptured cysts with anaphylactic shock | Procedure or surgery | – |
Primary outcome
THE PATIENT DIED due to probably anaphylactic shock
Time frame: 1 mounth
the patient probably had the rupture of cysts during the surgical procedure with anaphylactic shock as a complication
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Oct 2023.
- Individual participant dataSharing planned: Undecided
Related trials for Echinococcus Infections
RecruitingObservational study
Collection of Biological Samples From Patients With Echinococcosis and Implementation of a Home-made PCR Method
Echinococcosis
Not yet recruitingEarly Phase 1
5G Remote Robotic Surgery for Hepatic Echinococcosis in High-Altitude Region
Hepatic Echinococcosis
RecruitingObservational study
IM Bands in Inactive Hepatic CE
Cystic Echinococcosis
Recruiting
Biliary Fistulas in Surgery of Liver Echinococcosis
Echinococcosis, Hepatic, Biliary Fistula
RecruitingObservational study
Presentation of Protoscolexes and Acephalocysts in the Fibrous Capsule Area of the Liver With Echinococcosis
Echinococcosis, Hepatic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Echinococcus Infections, run by Faculty Of Medicine And Pharmacy, Casablanca at 1 site in Morocco.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 Oct 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Morocco. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
THE PATIENT DIED due to probably anaphylactic shock (time frame: 1 mounth). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Oct 2023.